Aclidinium bromide plus eformoterol fumarate dihydrate

PBAC's latest decision on Aclidinium bromide plus eformoterol fumarate dihydrate: Recommended with restriction (2015). Considered for Treatment of chronic obstructive pulmonary disease (COPD) in patients stabilised on a combination of a long-acting muscarinic antagonist and long-acting beta-2 agonist.

Eligible population

Adults with moderate to severe COPD who have been stabilised on a combination of a long-acting muscarinic antagonist and long-acting beta-2 agonist.

Therapy area

Respiratory

Line of therapy

Any

Evidence base

RCT

Primary endpoint

Trough FEV1

Pivotal trial size

1,254 patients

Key trials

ACLIFORM, AUGMENT, SHINE, ENLIGHTEN, Donohue (2013)

Comparator

glycopyrronium/indacaterol FDC and umeclidinium/vilanterol FDC

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis conducted; no ICER calculated by design.

Similar precedents

• Aclidinium bromide
  similarity 0.79
• Umeclidinium + vilanterol
  similarity 0.76
• Indacaterol with glycopyrronium
  similarity 0.75
• Budesonide with glycopyrronium and formoterol
  similarity 0.72
• Indacaterol + glycopyrronium
  similarity 0.72
• Fluticasone furoate + vilanterol
  similarity 0.72